Detection of prevalence and severity of (subclinical) pulmonary artery emboli in the setting of COVID-19 disease using pulmonary ventilation/perfusion scintigraphy.

Detection of prevalence and severity of (subclinical) pulmonary artery emboli in the setting of COVID-19 disease using pulmonary ventilation/perfusion scintigraphy. - COVID-19 SPECT 01

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023606

Enrollment

Registered

2022-03-25

Start date

2021-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I26

Interventions

Group 1: Scintigraphy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with condition after PCR-proven SARS-CoV-2 infection and again negative PCR after recovery, regardless of further therapeutic measures, if the patients had to undergo hospitalisation in connection with the SARS-CoV-2 infection.

Exclusion criteria

Exclusion criteria: 1. pregnant or breastfeeding women 2. minors and patients with mental illness or such patients, who are unable to give written informed consent to the study 3. haemodynamically unstable patients or patients with acute myocardial infarction (ST-segment elevation, creatinine kinase or MB isoenzyme elevation > 3 times the normal value) 4. bronchial asthma/COPD 5. known allergy to chicken egg white or charcoal 6. known cardiac right-to-left shunt 7. renal insufficiency (serum creatinine >2.0 mg/dl or GFR <30ml/min) 8. patients with claustrophobia 9. patients with previously diagnosed pulmonary artery embolism

Design outcomes

Primary

Measure	Time frame
Ventilation/perfusion scintigraphy of patients immediately after COVID 19 infection requiring hospital admission (1-2 weeks after negative throat swab/rinse PCR for SARS-CoV-2) and at 3 and 12 month intervals will be used to assess the frequency, time of manifestation and persistence, if any, of pulmonary artery emboli occurring in patients with COVID 19 infection.	—

Countries

Germany

Contacts

Public ContactChristian Pfob

Universitätsklinikum Augsburg

Studien.Nuk@uk-augsburg.de0821-400-2052

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026